Warp Speed For All And A Boost For Small Biotechs In Trump’s Second Term, Ex-Official Says

 
• By Sarah Karlin-Smith

Former Trump adviser Tomas Philipson anticipates the FDA will undergo a deregulatory push during President Trump’s second term and emphasize speeding drugs to market.

Training moving fast.
The FDA may aim to speed up agency reviews during Trump's second term. (Shutterstock)

More from Elections

More from Legislation